Tasir Shamsul Haque

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 11 EPO patents. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tasir Shamsul Haque. Retrieved from https://idiyas.com/inventor/tasir-shamsul-haque

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 10)

Average Co-Inventor Count = 8.5

ph-index = 4

Forward Citations = 52(Granted Patents)

Company Filing History:

15 out of 3,742

Bristol-Myers Squibb Compnay

patents

Years Active: 2008-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673042 - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds (2026-07-07),

2. 12030878 - Substituted indole ether compounds (2024-07-09),

3. 11878975 - Substituted indole compounds useful as TLR inhibitors (2024-01-23),

4. 11739098 - Substituted indole compounds (2023-08-29),

5. 11672780 - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds (2023-06-13),

6. 11447466 - Substituted indole compounds useful as inhibitors of TLR7/8/9 (2022-09-20),

7. 11420973 - Amide substituted indole compounds useful as TLR inhibitors (2022-08-23),

8. 11420958 - Aryl and heteroaryl substituted indole compounds (2022-08-23),

9. 11306092 - Amino indole compounds useful as TLR inhibitors (2022-04-19),

10. 11180474 - Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors (2021-11-23),

11. 10912766 - [1,2,4]triazolo[1,5-A]pyridinyl substituted indole compounds (2021-02-09),

12. 10660877 - Pyridyl substituted indole compounds (2020-05-26),

13. 7534763 - Sustained release GLP-1 receptor modulators (2009-05-19),

14. 7417028 - Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions (2008-08-26),

15. 7381732 - Pyrazolobenzamides and derivatives as factor Xa inhibitors (2008-06-03),

Title: Tasir Shamsul Haque: Innovator in Pharmaceutical Compounds

Introduction:

Tasir Shamsul Haque, an inventive mind based in Yardley, PA, has made significant contributions to the field of pharmaceuticals with a impressive portfolio of patents.

Latest Patents:

Haque's latest patents include "Substituted Indole Compounds Useful as TLR Inhibitors," focusing on compounds that inhibit signaling through Toll-like receptors 7, 8, and 9, aiding in the treatment of inflammatory and autoimmune diseases. Another notable patent is for "Substituted Indole Compounds," showcasing his ongoing dedication to developing pharmaceutical solutions.

Career Highlights:

Haque is a valued member of Bristol-Myers Squibb Company, where his expertise and creativity have propelled the development of innovative pharmaceutical compounds. With a total of 13 patents to his name, Haque continues to push boundaries in the industry.

Collaborations:

Throughout his career, Haque has collaborated with esteemed professionals such as Alaric J Dyckman and Dharmpal S Dodd. Together, they have worked on groundbreaking projects that have the potential to revolutionize the field of pharmaceuticals.

Conclusion:

In conclusion, Tasir Shamsul Haque stands as a pioneering figure in the realm of pharmaceutical innovations. His dedication to creating novel solutions for treating inflammatory and autoimmune diseases has positioned him as a key player in the industry, with a bright future ahead.

Profile summary based on public USPTO records.